GE Healthcare Life Sciences to Build KUBio Modular Biopharmaceutical Factory for JHL Biotech in China
9/25/2013 9:37:52 AM
CHALFONT ST GILES, England & WUHAN, China--(BUSINESS WIRE)--GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE), and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, today announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech. The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China. Worldwide demand for biopharmaceuticals, such as antibodies for the treatment of cancer and a new generation of innovative vaccines, is increasing dramatically. KUBio is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility. Pre-designed to meet cGMP requirements, KUBio helps manufacturers, such as JHL Biotech, respond to local healthcare needs and support global customers in bringing life-saving treatments to market more quickly.
Help employers find you! Check out all the jobs and post your resume.
comments powered by